Information for healthcare professionals
Reference: J Interven Cardiol 2016; 29:248–256. Cardiogenic shock (CS) is the leading cause of death after acute myocardial infarction (AMI) and occurs in up to 10% of cases.1 Notably, the incidence of CS is higher in women presenting with STEMI than men (11.6% vs. 8.3%, p < 0.01).2 Previous studies evaluating the impact of CS … Continue reading “Impella Support Pre-PCI for AMICS is Associated with Higher Survival in Women”
Impella RP® Support for Univentricular Shock Dr. Navin Kapur, an interventional heart failure specialist at Tufts Medical Center, presents a case of univentricular shock in a 60-year-old patient with late presentation RVMI and 3 vessel disease. This case illustrates a hemodynamics-based decision-making process leading to optimal patient outcome. Dr. Kapur explains that his surgical team … Continue reading “Case Study Video: Right Ventricular Failure”
Use of Impella RP and Impella 2.5 for MitraClip Procedure Dr. Kamran Muhammad discusses a challenging case illustrating the decision to use Impella RP® with Impella 2.5® to provide biventricular support. Dr. Muhammad is a subspecialist in interventional cardiology at Oklahoma Heart Institute in Tulsa, Oklahoma. The patient was an 81-year-old female presenting to the … Continue reading “Biventricular Support in Procedural Cardiogenic Shock”
Instituting a Cardiogenic Shock Protocol to Improve Outcomes Alexander Truesdell, MD and Behnam Tehrani, MD, interventional cardiologists at INOVA Heart and Vascular Institute discuss their experience implementing a cardiogenic shock protocol at INOVA. Data from their experience was recently published in the Journal of the American College of Cardiology. After Inova instituted a best practice … Continue reading “INOVA Heart and Vascular Heart Recovery Initiative”
Dr. Alex Truesdell of Virginia Heart discusses how a “team of teams” approach to treating cardiogenic shock can standardize care and improve outcomes. He also discusses the recent improvement in cardiogenic shock survival at Inova Heart and Vascular. After Inova Heart and Vascular Institute instituted a best practice protocol that includes early use of percutaneous … Continue reading “Dr. Alexander Truesdell: “Team of Teams” for Treating Cardiogenic Shock”
Dr. Alexander Truesdell, Interventional Cardiologist at Inova Heart and Vascular Institute discusses his editorial, the War on Shock, published in the Journal of Invasive Cardiology. The editorial compares his experience as a military physician with his experience as a cardiologist treating cardiogenic shock. Watch the video to learn which systems of care Dr. Truesdell suggests … Continue reading “Identifying Cardiogenic Shock Early with a Heart Team Approach”
A preponderance of evidence from the FDA cVAD Study, Impella Quality Assurance Database and physician-initiated National Cardiogenic Shock Initiative support the recommendation that placing Impella 2.5 or Impella CP pre-PCI improves outcomes.
Despite significant reduction in mortality in ST-segment elevation myocardial infarction (STEMI) following primary percutaneous coronary intervention (PCI), mortality rates in AMI complicated by cardiogenic shock (AMI-CGS) continues to be unacceptably high at about 50%.1 For Best Outcomes in AMI Cardiogenic Shock, Place Impella® or Impella CP® Pre-PCI Download this short bulletin that references scientific research … Continue reading “Early Initiation of Impella Support Pre-PCI: Key to Consistent and Reproducible Outcome of Improved Survival in AMICS”
Reference: J Am Coll Cardiol 2018; 72:1972-80 Cardiogenic shock continues to be the leading cause of death in patients with acute myocardial infarction (AMI).1 Despite implementation of guideline-recommended early revascularization, mortality rates in AMI complicated by cardiogenic shock (AMICS) remains constant at about 50%. Given that about 60,000 patients with AMI develop CS every year,2 … Continue reading “Improving Survival in Cardiogenic Shock by Adopting a Uniform Approach to Systems of Care”
By completing this form, you are consenting to receiving emails regarding updates to the program, downloadable templates, case reviews, specialists opinions, and best practices.
Your personal information is important to us. Review our Privacy Policy and Terms of Use to learn how Abiomed protects your data.